Přehled o publikaci
2025
Targeting proteostasis in multiple myeloma through inhibition of LTK
VATSVEEN, Thea Kristin; Mariaserena GILIBERTO; Valgerdur BJORNSDOTTIR; Federica CENTONZE; Andrej BEŠŠE et. al.Základní údaje
Originální název
Targeting proteostasis in multiple myeloma through inhibition of LTK
Autoři
VATSVEEN, Thea Kristin; Mariaserena GILIBERTO; Valgerdur BJORNSDOTTIR; Federica CENTONZE; Andrej BEŠŠE; Yannick FREY; Sigrid S SKANLAND; Anders TVEITA; Amin ALIREZAYLAVASANI; John Franklin IMBERY; Kristine MISUND; Veronika REITERER; Muhammad ZAHOOR; Christoph DRIESSEN; Lenka BEŠŠE; Kjetil TASKEN; Fredrik H SCHJESVOLD; Hesso FARHAN a Ludvig A MUNTHE
Vydání
Leukemia, London, Nature Publishing Group, 2025, 0887-6924
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Stát vydavatele
Velká Británie a Severní Irsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Organizace
Lékařská fakulta – Masarykova univerzita – Repozitář
UT WoS
001527724200001
EID Scopus
2-s2.0-105010413889
Klíčová slova anglicky
multiple myeloma; LTK kinase; proteostasis; ALK inhibitors; immunoglobulin secretion
Návaznosti
LX22NPO5102, projekt VaV.
Změněno: 21. 11. 2025 00:50, RNDr. Daniel Jakubík
Anotace
V originále
Multiple myeloma (MM) cells secrete high levels of immunoglobulin and are therefore addicted to mechanisms that maintain proteome homeostasis (proteostasis). While proteasome inhibitors that target the degradative aspect of proteostasis have proven effective, only limited attempts have been made to target protein secretion. Here we show that the receptor tyrosine kinase LTK is a regulatory node in the proteostasis network that responds to secretory load and helps cells maintain a high secretory output. LTK is a highly similar paralog to ALK and by repurposing existing ALK inhibitors, we demonstrate that targeting LTK causes immunoglobulin retention, ER stress and subsequent apoptosis of primary MM cells, even in patients refractory to proteasome inhibitors. Thus, LTK is a novel therapeutic target in the biosynthetic pathway of proteostasis, with significant potential for MM treatment.